终结罕见:英格兰间质性肺疾病负担演变——基于全国人群队列的趋势研究
本研究利用英格兰初级与次级电子健康记录链接数据,采用三种编码算法估算2005至2022年间所有间质性肺疾病(ILD)、特发性肺纤维化(IPF)及非IPF ILD的发病率、患病率和死亡率。结果显示2022年所有ILD、IPF及非IPF ILD的发病率较2005年高30%,自2018年起趋于平稳;IPF和非IPF ILD患病率分别增加6%和7%;IPF患者年龄性别调整死亡率降低15%。研究结论指出ILD已不再罕见,目前约有20万人患病、每年新诊断6万例。
要点
- 2022年所有ILD、IPF及非IPF ILD发病率较2005年高30%,2018年起趋于平稳。
- IPF和非IPF ILD患病率分别增加6%和7%,IPF调整死亡率降低15%。
- 整体ILD队列中位生存期为5.4年(IQR 1.88-13.03)。
核心结论
- ILD已不再罕见,当前英格兰约有20万人患病、每年新诊断6万例,医疗与研究投入需反映这一增长负担。
研究设计与样本
- 基于英格兰初级与次级电子健康记录链接的全国人群队列研究,采用三种编码算法估算2005至2022年发病率、患病率和死亡率。
主要发现
- 2022年所有ILD、IPF及非IPF ILD的发病率均较2005年高30%,自2018年起趋于平稳。
- 研究期间IPF患病率增加6%,非IPF ILD患病率增加7%。
- 2022年所有ILD及非IPF ILD的年龄性别调整死亡率与2005年相似,但IPF患者调整死亡率降低15%。
- 整体ILD队列中位生存期为5.4年(IQR 1.88-13.03)。
临床怎么用
- 呼吸科医生应认识到ILD(尤其是非IPF ILD)发病率与患病率持续上升,需加强早期识别与长期管理规划。
- IPF患者调整死亡率下降提示诊疗进步,但仍需关注整体ILD人群5.4年的中位生存期并优化随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The disease burden from interstitial lung diseases (ILDs) is thought to be increasing globally, but there is a paucity of data on epidemiological trends in non-idiopathic pulmonary fibrosis (IPF) ILD. We calculated incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD in England from 2005 to 2022 and investigated trends over time. METHODS: Using linked primary and secondary electronic healthcare records, we used three code-based algorithms to estimate incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD subtypes. We additionally stratified our results by sex, age-group and region. Poisson regression was used to investigate changes to trends over time. We used Kaplan-Meier methods to calculate median survival. RESULTS: There were 153 975 incident cases of ILD in either primary or secondary care records. Incidence rates of all ILD, IPF and non-IPF ILD were 30% higher in 2022 compared with 2005, with rates plateauing from 2018 onwards. The prevalence of IPF and non-IPF ILD increased by 6% and 7%, respectively, over the study period. Mortality rates adjusted for age and sex in people with all ILD and non-IPF ILD were similar in 2022 compared with 2005 but in people with IPF it was 15% lower. Median survival of our overall ILD cohort was 5.4 years (IQR 1.88-13.03). CONCLUSIONS: Our population-based study highlights that ILD are no longer rare. Currently, there are 200 000 people living with ILD and 60 000 new cases are diagnosed each year. Healthcare and research funding needs to reflect this growing burden.
引用
- Massen GM, Morgan AD, George PM, et al. End of rarity: the evolving burden of interstitial lung diseases in England - trends from a national population-based cohort study. Thorax. 2026. PMID: 42823350. doi:10.1136/thorax-2026-224977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。